The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Development of Nanoparticles for Antimicrobial Drug Delivery
Abstract
This review focuses on the development of nanoparticle systems for antimicrobial drug delivery. Numerous antimicrobial drugs have been prescribed to kill or inhibit the growth of microbes such as bacteria, fungi and viruses. Even though the therapeutic efficacy of these drugs has been well established, inefficient delivery could result in inadequate therapeutic index and local and systemic side effects including cutaneous irritation, peeling, scaling and gut flora reduction. Nanostructured biomaterials, nanoparticles in particular, have unique physicochemical properties such as ultra small and controllable size, large surface area to mass ratio, high reactivity, and functionalizable structure. These properties can be applied to facilitate the administration of antimicrobial drugs, thereby overcoming some of the limitations in traditional antimicrobial therapeutics. In recent years, encapsulation of antimicrobial drugs in nanoparticle systems has emerged as an innovative and promising alternative that enhances therapeutic effectiveness and minimizes undesirable side effects of the drugs. Here the current progress and challenges in synthesizing nanoparticle platforms for delivering various antimicrobial drugs are reviewed. We also call attention to the need to unite the shared interest between nanoengineers and microbiologists in developing nanotechnology for the treatment of microbial diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664 · cited 1×
“Liposome structure was first described in 1965 [9], and they were proposed as a drug delivery nanoparticle platform in 1970s [10].”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“Many advantages of nanoparticle-based drug delivery have been recognized, including improving serum solubility of the drugs, prolonging the systemic circulation lifetime, releasing drugs at a sustained and controlled manner, preferentially delivering drugs to the tissues and cells of interest, and concurrently deliver…”
BackgroundSolid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759
Biodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Self-citationAbout Dendrimers: Structure, Physical Properties, and Applications
Bosman, A. W., Janssen, H. M., & Meijer, E. W. (1999) · Chemical Reviews · doi:10.1021/cr970069y · Cited by 2,343
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00118-7 · Cited by 2,113
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777
The emerging nanomedicine landscape
Wagner, V., Dullaart, A., Bock, A.-K., & Zweck, A. (2006) · Nature Biotechnology · doi:10.1038/nbt1006-1211 · Cited by 1,630
Convergent Dendrons and Dendrimers: from Synthesis to Applications
Grayson, S. M., & Fréchet, J. M. J. (2001) · Chemical Reviews · doi:10.1021/cr990116h · Cited by 1,619
Dendrimers and dendritic polymers in drug delivery
Gillies, E. R., & Fréchet, J. M. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03276-3 · Cited by 1,367
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Pouton, C. W. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00167-6 · Cited by 1,230
Polymers for the sustained release of proteins and other macromolecules
LANGER, R., & FOLKMAN, J. (1976) · Nature · doi:10.1038/263797a0 · Cited by 1,182
Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes
Olson, F., Hunt, C. A., Szoka, F. C., Vail, W. J., & Papahadjopoulos, D. (1979) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(79)90085-3 · Cited by 1,126
Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism
zur Mühlen, A., Schwarz, C., & Mehnert, W. (1998) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(97)00150-1 · Cited by 945
Trends and Developments in Liposome Drug Delivery Systems
Lian, T., & Ho, R. J. Y. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1023 · Cited by 907
Nanomedicine: Developing smarter therapeutic and diagnostic modalities☆
FAROKHZAD, O., & LANGER, R. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.011 · Cited by 800
The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
Gelperina, S., Kisich, K., Iseman, M. D., & Heifets, L. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-613pp · Cited by 745
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
Gu, F., Zhang, L., Teply, B. A., Mann, N., Wang, A., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711714105 · Cited by 715
Self-citationThe future challenges facing the development of new antimicrobial drugs
Coates, A., Hu, Y., Bax, R., & Page, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd940 · Cited by 704
Souto, E. B., Wissing, S. A., Barbosa, C. M., & Müller, R. H. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.02.032 · Cited by 692
Interactions between dendrimer biocides and bacterial membranes
Chen, C. Z., & Cooper, S. L. (2002) · Biomaterials · doi:10.1016/s0142-9612(02)00036-4 · Cited by 663
Preparation and characterization of liposomes as therapeutic delivery systems: a review
Vemuri, S., & Rhodes, C. T. (1995) · Pharmaceutica Acta Helvetiae · doi:10.1016/0031-6865(95)00010-7 · Cited by 564
Microbiology of airway disease in patients with cystic fibrosis
Gilligan, P. H. (1991) · Clinical Microbiology Reviews · doi:10.1128/cmr.4.1.35 · Cited by 529
Dendrimer−Silver Complexes and Nanocomposites as Antimicrobial Agents
Balogh, L., Swanson, D. R., Tomalia, D. A., Hagnauer, G. L., & McManus, A. T. (2001) · Nano Letters · doi:10.1021/nl005502p · Cited by 412
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Walsh, T. J., Goodman, J. L., Pappas, P., Bekersky, I., Buell, D. N., Roden, M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401
Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin
Cavalli, R., Gasco, M. R., Chetoni, P., Burgalassi, S., & Saettone, M. F. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00080-7 · Cited by 389
Cosmetic applications for solid lipid nanoparticles (SLN)
Wissing, S. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00684-1 · Cited by 364
AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
Adler-Moore, J., & Proffitt, R. T. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.21 · Cited by 339
Update in Antifungal Therapy of Dermatophytosis
Gupta, A. K., & Cooper, E. A. (2008) · Mycopathologia · doi:10.1007/s11046-008-9109-0 · Cited by 329
Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318 · cited 1×
“SLNs can facilitate the delivery of anti-tuberculosis drugs such as rifampin, isoniazidand pyrazinamide to the lungs as well as to the lymphatic systems [60].”
BackgroundHow to Stabilize Phospholipid Liposomes (Using Nanoparticles)
Zhang, L., & Granick, S. (2006) · Nano Letters · doi:10.1021/nl052455y · Cited by 278
Self-citationAdler-moore, J. P., & Proffitt, R. T. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150729 · Cited by 251
Müller, R. (1996) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(96)04539-5 · Cited by 242
Bhalekar, M. R., Pokharkar, V., Madgulkar, A., Patil, N., & Patil, N. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9199-0 · Cited by 241
Ahmad, Z., Pandey, R., Sharma, S., & Khuller, G. K. (2006) · PubMed · Cited by 231
Johnson, S. M., Bangham, A. D., Hill, M. W., & Korn, E. D. (1971) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(71)90184-2 · Cited by 222
Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles
Videira, M. A., Botelho, M. F., Santos, A. C., Gouveia, L. F., Pedroso de Lima, J. J., & Almeida, A. J. (2002) · Journal of Drug Targeting · doi:10.1080/1061186021000054933 · Cited by 213
The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes
Yang, D., Pornpattananangkul, D., Nakatsuji, T., Chan, M., Carson, D., Huang, C.-M., & Zhang, L. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.033 · Cited by 212
Self-citationSLN and NLC for topical delivery of ketoconazole
Souto, E. B., & Müller, R. H. (2005) · Journal of Microencapsulation · doi:10.1080/02652040500162436 · Cited by 208
Cheng, Y., Qu, H., Ma, M., Xu, Z., Xu, P., Fang, Y., & Xu, T. (2007) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.12.035 · Cited by 206
Investigations on the occlusive properties of solid lipid nanoparticles (SLN).
Wissing, S. A., Lippacher, A., & Müller, R. (2001) · PubMed · Cited by 199
Ma, M., Cheng, Y., Xu, Z., Xu, P., Qu, H., Fang, Y., Xu, T., & Wen, L. (2007) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.07.015 · Cited by 190
Walsh, T. J., Yeldandi, V., McEvoy, M., Gonzalez, C., Chanock, S., Freifeld, A., Seibel, N. I., Whitcomb, P. O., Jarosinski, P., Boswell, G., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2391 · Cited by 189
Kelsey, S., Goldman, J., McCann, S., Newland, A., Scarffe, J., Oppenheim, B., & Mufti, G. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701543 · Cited by 173
Turos, E., Shim, J.-Y., Wang, Y., Greenhalgh, K., Reddy, G. S. K., Dickey, S., & Lim, D. V. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.098 · Cited by 169
Mugabe, C., Halwani, M., Azghani, A. O., Lafrenie, R. M., & Omri, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01547-05 · Cited by 169
Eldem, T., Speiser, P., & Hincal, A. (1991) · Pharmaceutical Research · doi:10.1023/a:1015874121860 · Cited by 165
Devarakonda, B., Hill, R. A., Liebenberg, W., Brits, M., & de Villiers, M. M. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.07.023 · Cited by 162
Omri, A., Suntres, Z. E., & Shek, P. N. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01346-1 · Cited by 159
Intracellular Delivery of Saquinavir in Biodegradable Polymeric Nanoparticles for HIV/AIDS
Shah, L. K., & Amiji, M. M. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9101-7 · Cited by 155
Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles
Fattal, E., Youssef, M. T., Couvreur, P., & Andremont, A. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1540 · Cited by 149
Sanna, V., Gavini, E., Cossu, M., et al. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.8.0002 · Cited by 129
Lymphatic targeting of zidovudine using surface-engineered liposomes
Kaur, C. D., Nahar, M., & Jain, N. K. (2008) · Journal of drug targeting · doi:10.1080/10611860802475688 · Cited by 127
Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model
Pandey, R., & Khuller, G. K. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl128 · Cited by 118
Selected antimicrobial agents: mechanisms of action, side effects and drug interactions
Walker, C. (1996) · Periodontology 2000 · doi:10.1111/j.1600-0757.1996.tb00066.x · Cited by 116
Umamaheshwari, R. B., & Jain, N. K. (2003) · Journal of drug targeting · doi:10.1080/10611860310001647771 · Cited by 110
Mosqueira, V. C. F., Loiseau, P. M., Bories, C., Legrand, P., Devissaguet, J., & BARRATT, G. M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1222-1228.2004 · Cited by 109
AmBisome targeting to fungal infections.
Adler‐Moore, J. (1994) · PubMed · Cited by 107
Bargoni, A., Cavalli, R., Zara, G. P., Fundaro', A., Caputo, O., & Gasco, M. R. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0813 · Cited by 101
Onyeji, C. O., Nightingale, C. H., & Marangos, M. N. (1994) · Infection · doi:10.1007/bf01715542 · Cited by 89
The use of SLN and NLC as topical particulate carriers for imidazole antifungal agents.
Souto, E. B., & Müller, R. H. (2006) · PubMed · Cited by 83
Drug delivery strategies for improved azole antifungal action
Yang, W. P., Wiederhold, N. P., & Williams, R. O. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802457188 · Cited by 79
Fountain, M. W., Weiss, S. J., Fountain, A., Shen, A. J., & Lenk, R. P. (1985) · The Journal of Infectious Diseases · doi:10.1093/infdis/152.3.529 · Cited by 73
Fielding, R. M., Lewis, R. O., & Moon-McDermott, L. (1998) · Pharmaceutical Research · doi:10.1023/a:1011925132473 · Cited by 72 · cited 1×
“hydrogenated soy phosphatidylcholine, cholesterol, and distearoylphosphatidylglycerol (DSPG) amikacin gram-negative bacteria prolonged drug and exposure [78]”
BackgroundPegylated lysine based copolymeric dendritic micelles for solubilization and delivery of artemether.
Bhadra, D., Bhadra, S., & Jain, N. K. (2005) · PubMed · Cited by 72
Tyagi, R., Lala, S., Verma, A. K., Nandy, A. K., Mahato, S. B., Maitra, A., & Basu, M. K. (2005) · Journal of drug targeting · doi:10.1080/10611860500046732 · Cited by 70
Espuelas, S. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg351 · Cited by 70
Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis
Magallanes, M., Dijkstra, J., & Fierer, J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2293 · Cited by 67
Gaspar, R. S., Véronique Préat, A., Opperdoes, F. R., & Roland, M. (1992) · Pharmaceutical Research · doi:10.1023/a:1015807706530 · Cited by 64
Forestier, F., Gerrier, P., Chaumanrd, C., Quéro, A.-M., Couvreur, P., & Labarre, C. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/30.2.173 · Cited by 64
Delivery of antimicrobials to infected tissue macrophages
Bakker‐Woudenberg, I. A. J. M. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00037-8 · Cited by 51
Gangadharam, P. R., Ashtekar, D., Ghori, N., Goldstein, J. A., Debs, R. J., & Düzgüneş, N. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.3.425 · Cited by 50
Takemoto, K., Yamamoto, Y., Ueda, Y., Sumita, Y., Yoshida, K., & Niki, Y. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh055 · Cited by 49
Stöckler, S., Lackner, H., Ginter, G., Schwinger, W., Plecko, B., & Müller, W. (1993) · European Journal of Pediatrics · doi:10.1007/bf01957220 · Cited by 10
Cited by
The antimicrobial activity of nanoparticles: present situation and prospects for the future
Wang, L., Hu, C., & Shao, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s121956 · Cited by 4,062
“34 This section focuses on the distinct features and complementary advantages of using NPs/nanotechnologies as antibacterial agents compared with traditional antibiotics, which can be summarized as follows: 1) overcoming the existing antibiotic resistance mechanisms that are listed in the…”
BackgroundSelf-citationAntimicrobial Peptides: An Emerging Category of Therapeutic Agents
Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00194 · Cited by 1,927
Huh, A. J., & Kwon, Y. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.002 · Cited by 1,864
Nanotechnology as a therapeutic tool to combat microbial resistance
Pelgrift, R. Y., & Friedman, A. J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.011 · Cited by 1,432
Advanced materials and processing for drug delivery: The past and the future
Zhang, Y., Chan, H. F., & Leong, K. W. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.003 · Cited by 1,000
Metadata
- Authors
- Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-M.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-02-01
- Volume
- 17
- Issue
- 6
- Pages
- 585-594
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2112487751
- Cited by
- 886
- References
- 78
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.